Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Cut to $3.50 by Analysts at HC Wainwright

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective lowered by HC Wainwright from $4.00 to $3.50 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com upgraded Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th.

Adaptimmune Therapeutics Trading Up 0.5 %

Shares of Adaptimmune Therapeutics stock traded up $0.00 during trading on Thursday, hitting $0.59. 2,817,898 shares of the stock traded hands, compared to its average volume of 1,694,537. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. Adaptimmune Therapeutics has a 52 week low of $0.42 and a 52 week high of $2.05. The firm’s fifty day moving average is $0.89 and its 200-day moving average is $1.04.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 83.38%. The company had revenue of $128.23 million during the quarter, compared to the consensus estimate of $58.00 million. As a group, equities research analysts predict that Adaptimmune Therapeutics will post -0.23 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Long Focus Capital Management LLC lifted its holdings in shares of Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after purchasing an additional 1,662,184 shares during the last quarter. Baillie Gifford & Co. grew its holdings in Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after purchasing an additional 1,626,657 shares during the period. Renaissance Technologies LLC lifted its stake in Adaptimmune Therapeutics by 28.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after buying an additional 394,566 shares in the last quarter. Vontobel Holding Ltd. raised its position in shares of Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 30,000 shares during the last quarter. Finally, Fullcircle Wealth LLC acquired a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth $33,000. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.